Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Athena Breast Health Network Investigators"'
Autor:
Tianyi Wang, Mandy Che, Yash S. Huilgol, Holly Keane, Deborah Goodman, Rashna Soonavala, Elissa Ozanne, Yiwey Shieh, Jeffrey K. Belkora, Allison Stover Fiscalini, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among participants with high risk of breast cancer to validate whether a virtual breast healt
Externí odkaz:
https://doaj.org/article/0d40d24fcd9f4f33a313510e8fa492e4
Autor:
Yash S. Huilgol, Holly Keane, Yiwey Shieh, Robert A. Hiatt, Jeffrey A. Tice, Lisa Madlensky, Leah Sabacan, Allison Stover Fiscalini, Elad Ziv, Irene Acerbi, Mandy Che, Hoda Anton-Culver, Alexander D. Borowsky, Sharon Hunt, Arash Naeim, Barbara A. Parker, Laura J. van ‘T Veer, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which
Externí odkaz:
https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80
Autor:
Jane M Wei, Paul Kim, Cheryl Ewing, Jasmine Wong, Laura J Esserman, Michael D Alvarado, Abimbola O Olusanya, Skye Stewart, Ashley Tydon, Parima Daroui, Jeffrey V Kuo, Hannah L Park, Karen T Lane, Eliza Jeong, Kelsey Brown, Ava Hosseini, Barbara A Parker, Sarah L Blair, Athena Breast Health Network Investigators, Frederick Baehner, Olivier Harismendy, Antonia Petruse, Carlie K Thompson, Helena R Chang, Alexander D Borowsky, Christina Yau, Gillian L Hirst, Richard J Bold, Rita A Mukhtar
Publikováno v:
Cancer Research. 80:OT3-09
Background: Ductal carcinoma in situ (DCIS) now represents nearly a quarter of newly diagnosed breast cancers in the United States. Standard-of-care treatment for DCIS is aggressive local therapy consisting of either mastectomy or breast conserving s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c2533d50b993a1cac22f32742ed205a
https://doi.org/10.1158/1538-7445.sabcs19-ot3-09-01
https://doi.org/10.1158/1538-7445.sabcs19-ot3-09-01
Autor:
Shieh, Yiwey, Eklund, Martin, Madlensky, Lisa, Sawyer, Sarah D., Thompson, Carlie K., Fiscalini, Allison Stover, Ziv, Elad, van't Veer, Laura J., Esserman, Laura J., Tice, Jeffrey A., Stover Fiscalini, Allison, Athena Breast Health Network Investigators
Publikováno v:
JNCI: Journal of the National Cancer Institute; May2017, Vol. 109 Issue 5, p1-8, 8p, 3 Charts